Overall survival in first-line HR+/HER2- advanced breast cancer in the era of CDK4/6 inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Overall survival in first-line HR+/HER2- advanced breast cancer in the era of CDK4/6 inhibitors

Published:2024-08 Issue:8 Volume:35 Page:689-691
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Sánchez-Bayona Rodrigo,Oliveira Mafalda^ORCID

Publisher

Elsevier BV

Reference21 articles.

1. Palbociclib and letrozole in advanced breast cancer;Finn;N Engl J Med,2016

2. Ribociclib as first-line therapy for HR-positive, advanced breast cancer;Hortobagyi;N Engl J Med,2016

3. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer;Goetz;J Clin Oncol,2017

4. Overall survival with ribociclib plus letrozole in advanced breast cancer;Hortobagyi;N Engl J Med,2022

5. Updated overall survival of ribociclib plus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: A phase III randomized clinical trial;Lu;Clin Cancer Res,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP